| CVS |
Report |
Adjusted EPS |
BEAT |
pred ~$1.90 vs. cons $1.84 |
MEDIUM |
| CVS |
Report |
Revenue |
IN-LINE |
pred ~$100.8B vs. cons $100.09B |
MEDIUM |
| CVS |
Report |
Health Care Benefits medical benefit ratio |
BEAT |
pred ~89.0% vs. cons 90.1% |
LOW |
| CVS |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$7.40-$7.60 vs. cons $7.46 (FY2026) |
MEDIUM |
| CVS |
Guide |
Health Care Benefits adjusted operating income guidance |
BETTER |
guide ~$4.15B-$4.49B vs. cons $4.30B (FY2026) |
LOW |
| CVS |
Guide |
Medical benefit ratio guidance |
BETTER |
guide ~90.0% vs. cons 90.3% (FY2026) |
LOW |
| CVS |
Guide |
Operating cash flow guidance |
BETTER |
guide ~$10.0B vs. cons $9.8B (FY2026) |
MEDIUM |
| CVS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| CVS |
Return |
5-day cumulative residual |
+1.2% (FADE) |
Aetna cost performance and a modest FY2026 raise should drive the initial upside, but the raise is likely concentrated in Q2 and reserve/current-year favorability rather than materially higher second-half earnings. With the stock already pricing in a strong recovery, limited upward revision to implied Q3-Q4 and 2027 estimates should cause part of the day-1 move to fade. |
MEDIUM |